Published in Br J Dermatol on August 01, 2004
Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med (2005) 4.04
Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris. Ther Clin Risk Manag (2008) 1.04
Moderate and severe plaque psoriasis: cost-of-illness study in Italy. Ther Clin Risk Manag (2008) 0.93
Calcipotriol and betamethasone dipropionate in the treatment of mild-to-moderate psoriasis: a cost-effectiveness analysis of the ointment versus gel formulation. Clinicoecon Outcomes Res (2012) 0.83
Efalizumab in the treatment of psoriasis. Biologics (2007) 0.82
Regulation of cytokines by small RNAs during skin inflammation. J Biomed Sci (2010) 0.81
Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists. Br J Clin Pharmacol (2011) 0.79
Pneumococcal polysaccharide vaccination in adults undergoing immunosuppressive treatment for inflammatory diseases--a longitudinal study. Arthritis Res Ther (2015) 0.75
Emerging treatments in the management of psoriasis: biological targeting with ustekinumab. Clin Cosmet Investig Dermatol (2009) 0.75
Dynamic QuantiFERON Response in Psoriasis Patients Taking Long-Term Biologic Therapy. Dermatol Ther (Heidelb) (2013) 0.75
Bone marrow cells regenerate infarcted myocardium. Nature (2001) 21.24
A peptide antibiotic from human skin. Nature (1997) 7.64
The DNA sequence and comparative analysis of human chromosome 20. Nature (2002) 7.40
Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med (1995) 7.21
Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A (2001) 7.19
Isolation and characterization of human beta -defensin-3, a novel human inducible peptide antibiotic. J Biol Chem (2000) 6.19
Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol (1993) 5.51
Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med (2001) 5.14
The DNA sequence and analysis of human chromosome 6. Nature (2003) 4.75
Purification and partial biochemical characterization of a human monocyte-derived, neutrophil-activating peptide that lacks interleukin 1 activity. J Immunol (1987) 4.43
Disease concomitance in psoriasis. J Am Acad Dermatol (1995) 3.92
The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol (2001) 3.92
Evidence for compartmentalization of functional subsets of CD2+ T lymphocytes in atopic patients. J Immunol (1990) 3.77
European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol (2009) 3.56
Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol (1998) 3.38
Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med (1992) 3.20
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol (2007) 2.85
Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol (1985) 2.74
The effectiveness of one-to-one risk communication interventions in health care: a systematic review. Med Decis Making (2000) 2.68
Clinical guidelines: using clinical guidelines. BMJ (1999) 2.67
Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. J Immunol (1993) 2.63
CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest (1999) 2.58
Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol (2011) 2.55
Update on the use of ciclosporin in immune-mediated dermatoses. Br J Dermatol (2006) 2.49
Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. Hum Mol Genet (1997) 2.48
The DNA sequence and biological annotation of human chromosome 1. Nature (2006) 2.42
Differences in cellular infiltrate and extracellular matrix of chronic diabetic and venous ulcers versus acute wounds. J Invest Dermatol (1998) 2.30
A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med (1997) 2.29
Is screening for tuberculosis acceptable to immigrants? A qualitative study. J Public Health (Oxf) (2006) 2.28
Impact of obesity on arteriovenous fistula outcomes in dialysis patients. Kidney Int (2006) 2.24
Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. J Biol Chem (1990) 2.23
Antibiotic-resistant acne: lessons from Europe. Br J Dermatol (2003) 2.22
Transplanted adult bone marrow cells repair myocardial infarcts in mice. Ann N Y Acad Sci (2001) 2.17
Mortality from all causes and circulatory disease by country of birth in England and Wales 2001-2003. J Public Health (Oxf) (2007) 2.12
Elevated levels of NAP-1/interleukin-8 are present in the airspaces of patients with the adult respiratory distress syndrome and are associated with increased mortality. Am Rev Respir Dis (1992) 2.11
Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies. Hum Mol Genet (2001) 2.11
Treatment of mild to moderate seborrhoeic dermatitis with MAS064D (Sebclair), a novel topical medical device: results of a pilot, randomized, double-blind, controlled trial. J Eur Acad Dermatol Venereol (2008) 2.11
Structure determination of a human lymphocyte derived neutrophil activating peptide (LYNAP). Biochem Biophys Res Commun (1988) 2.10
Linkage analysis of human leukocyte antigen (HLA) markers in familial psoriasis: strong disequilibrium effects provide evidence for a major determinant in the HLA-B/-C region. Am J Hum Genet (1998) 2.09
Concordance between telepathologic diagnosis and conventional histopathologic diagnosis: a multiobserver store-and-forward study on 20 skin specimens. Arch Dermatol (2002) 2.07
Transient ferromagnetic-like state mediating ultrafast reversal of antiferromagnetically coupled spins. Nature (2011) 2.06
Secretion of novel and homologous neutrophil-activating peptides by LPS-stimulated human endothelial cells. J Immunol (1989) 2.04
Treatment of patients with systemic sclerosis with extracorporeal photochemotherapy (photopheresis). J Am Acad Dermatol (1999) 2.03
Characteristics of some co-trimoxazole-resistant Enterobacteriaceae from infected patients. J Clin Pathol (1972) 2.02
Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science (1994) 1.99
Cutaneous T-cell lymphoma in association with silicone breast implants. J Am Acad Dermatol (1995) 1.96
Identification of C5ades arg and an anionic neutrophil-activating peptide (ANAP) in psoriatic scales. J Invest Dermatol (1986) 1.96
Adverse reactions caused by consecutive injections of different fillers in the same facial region: risk assessment based on the results from the Injectable Filler Safety study. J Eur Acad Dermatol Venereol (2010) 1.93
IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress. Diabetes (2001) 1.92
Is research declining amongst gastroenterology trainees in the United Kingdom? Clin Med (2013) 1.91
Evidence produced in evidence based medicine needs to be relevant. BMJ (2000) 1.91
Functional subsets of allergen-reactive human CD4+ T cells. Immunol Today (1991) 1.89
Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol (2007) 1.86
Localization of psoriasis-susceptibility locus PSORS1 to a 60-kb interval telomeric to HLA-C. Am J Hum Genet (2000) 1.86
Treatment recommendations for psoriatic arthritis. Ann Rheum Dis (2008) 1.85
An enteric coronavirus infection of cats and its relationship to feline infectious peritonitis. Am J Vet Res (1981) 1.85
Antibody responses to Bordetella pertussis antigens and clinical correlations in elderly community residents. Clin Infect Dis (2000) 1.85
Effect of preoperative sonographic mapping on vascular access outcomes in hemodialysis patients. Kidney Int (2001) 1.84
The genetics of psoriasis. Arch Dermatol (1994) 1.84
A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol (2013) 1.83
Mortality from all cancers and lung, colorectal, breast and prostate cancer by country of birth in England and Wales, 2001-2003. Br J Cancer (2006) 1.82
Filaggrin loss-of-function mutations are associated with early-onset eczema, eczema severity and transepidermal water loss at 3 months of age. Br J Dermatol (2010) 1.81
Structural aspects of initial psoriatic lesions. Arch Dermatol Forsch (1974) 1.81
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) poisoning in Victor Yushchenko: identification and measurement of TCDD metabolites. Lancet (2009) 1.81
Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther (2001) 1.81
Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol (2007) 1.80
Effect of silicon on gastrointestinal absorption of aluminium. Lancet (1993) 1.80
Localization of neutrophil-activating peptide-1/interleukin-8-immunoreactivity in normal and psoriatic skin. J Invest Dermatol (1991) 1.79
Clinical signs that predict death in children with severe pneumonia. Pediatr Infect Dis J (1989) 1.77
Mutations in cornea-specific keratin K3 or K12 genes cause Meesmann's corneal dystrophy. Nat Genet (1997) 1.75
The development of guidelines for the treatment of vitiligo. Clinical Epidemiology Unit of the Istituto Dermopatico dell'Immacolata-Istituto di Recovero e Cura a Carattere Scientifico (IDI-IRCCS) and the Archives of Dermatology. Arch Dermatol (1999) 1.73
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol (2005) 1.72
Comparative study of 5% permethrin cream and 1% lindane lotion for the treatment of scabies. Arch Dermatol (1990) 1.72
Chloramphenicol alone versus chloramphenicol plus penicillin for bacterial meningitis in children. Lancet (1985) 1.71
Is there a rural/urban gradient in the prevalence of eczema? A systematic review. Br J Dermatol (2010) 1.68
In vitro and in vivo anti-melanoma effects of ciglitazone. J Invest Dermatol (2009) 1.67
Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study. Br J Dermatol (1998) 1.67
The skin immune system (SIS): distribution and immunophenotype of lymphocyte subpopulations in normal human skin. J Invest Dermatol (1987) 1.67
Melanoma in organ transplant recipients: clinicopathological features and outcome in 100 cases. Am J Transplant (2008) 1.65
Natural course of physical and chronic urticaria and angioedema in 220 patients. J Am Acad Dermatol (2001) 1.65
Erythrodermic psoriasis. Precipitating factors, course, and prognosis in 50 patients. J Am Acad Dermatol (1989) 1.65
Rosaceiform dermatitis with follicular Demodex after treatment of facial atopic dermatitis with 1% pimecrolimus cream. Dermatology (2003) 1.64
Dose-effects of 8-methoxypsoralen and UVA in cultured human lymphocytes. Br J Dermatol (1978) 1.64
Effect of anaesthesia on intracranial pressure in patients with space-occupying lesions. Lancet (1969) 1.64
Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with the acquired immunodeficiency syndrome in Germany. Arch Dermatol (1993) 1.63
Human atopen-specific types 1 and 2 T helper cell clones. J Immunol (1991) 1.62
Human epidermal Langerhans cells undergo profound morphologic and phenotypical changes during in vitro culture. J Invest Dermatol (1990) 1.62
Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab. Br J Dermatol (2004) 1.61
Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br J Dermatol (2013) 1.60
Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res (2010) 1.60